摘要
探究9次跨膜超家族蛋白2(transmembrane 9 superfamily protein member 2,TM9SF2)对于三阴性乳腺癌MDA-MB-231细胞增殖和转移的影响及其分子机制。采用Western blot实验检测三阴性乳腺癌细胞株MDA-MB-231和非致瘤的乳腺上皮细胞株MCF-10A中TM9SF2蛋白表达的情况;对高表达TM9SF2的三阴性细胞株MDA-MB-231进行基因沉默;采用MTS法检测细胞增殖活性,采用Transwell实验和划痕实验检测细胞的转移能力;采用Western blot实验检测细胞内增殖相关蛋白(PI3K、AKT、SRC和ERK)和转移相关蛋白(Snail、Slug和N-cadherin)的表达情况。Western blot实验证明,MDA-MB-231中TM9SF2蛋白的表达量高于MCF-10A细胞。与对照组相比,siRNA-TM9SF2转染组TM9SF2蛋白表达下调,细胞增殖活性降低,细胞转移能力减弱,PI3K、Snail、Slug和N-cadherin表达水平均降低,AKT蛋白磷酸化激活降低。研究结果表明,TM9SF2基因能促进三阴型乳腺癌MDA-MB-231细胞的增殖和转移。
The aim of this study was to investigate the effect of transmembrane 9 superfamily protein member 2(TM9SF2)in proliferation and migration of triple negative breast cancer cell line MDA-MB-231.The expression of TM9SF2 in triple negative breast cancer cell line MDA-MB-231 and nontumorigenic mammary epithelial cell line MCF-10A were measured by Western blot.MDA-MB-231 cells were treated with siRNA-TM9SF2 to knockdown the expression of TM9SF2.The effect of silencing TM9SF2 was measured with Western blot.The proliferation of cells was tested by MTS,and the migration was measured with Transwell and wound-healing assay.Proteins related to proliferation(PI3K,AKT,SRC and ERK)and migration(Snail,Slug and N-cadherin)were measured with Western blot.Protein expressions of TM9SF2 was better improved in triple negative breast cancer MDA-MB-231 cell line than MCF-10A.Compared with the control group,the siRNA-TM9SF2 infected group had lower expressions of PI3K,Snail,Slug and N-cadherin,and at the same time phosphorylation of AKT was decreased.The results suggest TM9SF2 can promote the proliferation and metastasis of triple negative breast cancer MDA-MB-231 cell line.
作者
王丽新
姜修博
郭巧珍
王籽橙
王勃
王玉霞
瞿文生
段小涛
WANG Lixin;JIANG Xiubo;GUO Qiaozhen;WANG Zicheng;WANG Bo;WANG Yuxia;QU Wensheng;DUAN Xiaotao(School of Chemical Engineering,Tianjin University,Tianjin 300350;State Key Laboratory of Antitoxic Drugs and Toxicology,Institute of Pharmacology and Toxicology,Academy of Military Medical Sciences,Beijing 100850;College of Biological and Pharmaceutical Engineering,Nanjing Tech University,Nanjing,211800,China)
出处
《中国药科大学学报》
CAS
CSCD
北大核心
2021年第5期609-613,共5页
Journal of China Pharmaceutical University